Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30364479 | 0.98 | NCF1 (0.46) | NCF1PLGPLATLMNACHRM2 | |
| SCHEMBL1009220 | 0.83 | CHRM2 (0.46) | CHRM2CHRM1CHRM3TPSAB1TPSD1 | |
| SCHEMBL4578231 | 0.82 | GAA (0.36) | TPSAB1TPSD1TPSG1GAAKDM1A | |
| SCHEMBL4578235 | 0.82 | ALOX5 (0.44) | TPSAB1TPSD1TPSG1GAAKDM1A | |
| SCHEMBL600521 | 0.82 | PLG (0.50) | NCF1PLGPLATLMNACHRM2 | |
| SCHEMBL23651895 | 0.80 | NCF1 (0.46) | NCF1PLGPLATLMNACHRM2 | |
| SCHEMBL8280193 | 0.80 | GAA (0.43) | CHRM1TPSAB1TPSD1TPSG1GAA | |
| SCHEMBL8065249 | 0.80 | ITGB3 (0.46) | TPSAB1TPSD1TPSG1KDM1A | |
| SCHEMBL22882344 | 0.80 | CPN1 (0.50) | NCF1PLGPLATLMNACHRM2 | |
| SCHEMBL14433549 | 0.80 | TPSAB1 (0.39) | TPSAB1TPSD1TPSG1GAAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572913-B2 | Inhibitors of Rho kinase; N-Benzyloxycarbonyl-4-[N''-(tert-butyloxycarbonyl)hydrazino]piperidine; 4-{[N''-(tert-butyloxycarbonyl)-N'-(1'-propyl)]hydrazino}piperidine | BIOAXONE THERAPEUTIQUE INC. (CA) | 2009-08-11 | — | — | US | disclosed |
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1720874-A1 | 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Bioaxone Therapeutique Inc. (CA) | 2006-11-15 | — | — | EP | disclosed |
| US-20050272751-A1 | 4-Substituted piperidine derivatives | BIOAXONE THERAPEUTIQUE INC. (CA) | 2005-12-08 | — | — | US | disclosed |
| WO-2005080394-A1 | 4-SUBSTITUTED PIPERIDINE DERIVATIVES | BIOAXONE THERAPEUTIQUE INC. (CA) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272751-A1 | 4-Substituted piperidine derivatives | RHOC, PRPH, RHOT2 | NCF1 1149/4885PLG 597/4885PLAT 976/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | NCF1 1292/4885PLG 125/4885PLAT 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.